Atovaquone proguanil labels and packages

Atovaquone proguanil
MALARONE® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Labels And Packages

Principal Display Panel NDC 0173-0675-01 MALARONE® (atovaquone and proguanil HCl) Tablets Each tablet contains 250 mg atovaquone and 100 mg proguanil HCl. Rx only 100 Tablets See accompanying prescribing information for Dosage and Administration. Store at 25oC (77oF); excursions permitted to 15o to 30oC (59oto 86oF) (see USP Controlled Room Temperature). Do not use if printed safety seal under cap is broken or missing. GlaxoSmithKline Research Triangle Park, NC 27709 Made in Canada Rev. 3/10 A079205

Principal Display Panel NDC 0173-0676-01 MALARONE® (atovaquone and proguanil HCl) Pediatric Tablets Each tablet contains 62.5 mg atovaquone and 25 mg proguanil HCl. Rx only 100 Tablets See accompanying prescribing information for Dosage and Administration. Store at 25oC (77oF); excursions permitted to 15o to 30oC (59oto 86oF) (see USP Controlled Room Temperature). Do not use if printed safety seal under cap is broken or missing. GlaxoSmithKline Research Triangle Park, NC 27709 Made in Canada Rev. 3/10 A079206

References

Adapted from the FDA Package Insert.